Added by | standudu |
---|---|
Group name | EquipeCTCS |
Item Type | Attachment |
Title | Texte intégral |
URL | https://link.springer.com/content/pdf/10.1007/s10549-021-06334-0.pdf |
Accessed | 2022/07/29 - 14:02:49 |
Date Added | 2022/07/29 - 12:02:49 |
Date Modified | 2022/07/29 - 12:02:49 |
Parent item | Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population |